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Abstract 
Several clinical studies have shown that moderate alcohol consumption is inversely associated 
with the risk of developing Type 2 Diabetes due to the positive action of alcohol on specific 
biomarkers of the disease.  Wines are very promising anti-diabetic beverages not only for their 
alcohol content but also for their composition in phenolic compounds. In this area, red wines have 
been extensively studied existing reports on their anti-diabetic potential. However, there are no 
studies regarding white wine, even though it is known to have similar or higher concentrations of 
hydroxycinnamic acids, which are potential anti-hyperglycemic agents. 
The aim of this thesis was to investigate the anti-hyperglycemic potential of white wines using 
chemical and cell-based assays. For this purpose, four wines were characterized in terms of 
phenolic composition and their capacity in inhibiting carbohydrate-digestion enzymes and glucose 
transporters using a Caco-2 cell model.  
Results showed that phytochemical composition varied greatly among all wines. Aveleda 
Alvarinho presented a higher concentration and more variety of phenolic compounds. This wine 
also showed the ability to inhibit α-amylase (IC50 199.5 mg GAE/L) and α-glucosidase, and 
improved the activity of acarbose when combined with this drug. Gallic acid was identified as 
being a major contributor for the α-glucosidase inhibition, with an IC50 value of 32.28 mg/L. In 
particular, when combined with acarbose, a synergistic effect was also observed. Additionally, 
the results obtained in Caco-2 cells revealed that Aveleda Alvarinho was able to inhibit glucose 
transporters, namely SGLT1 and GLUT2, in a dose dependent-manner (IC50 79.5 mg GAE/L and 
126.7 mg GAE/L, respectively). The digested fraction of this wine showed a slightly higher 
inhibition of glucose transport, whose effect was related with the phenolic metabolites produced 
during in vitro gastrointestinal digestion. 
Results of this thesis demonstrated that white wine can be considered as a promising source of 
new natural anti-hyperglycemic agents.   
 
Keywords: Type 2 diabetes; White wine; Polyphenols; SGLT1 and GLUT2 transporters; 
Carbohydrate-digestion enzymes; Caco-2 cells 
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Resumo 
Estudos clínicos mostraram que o consumo moderado de álcool se relaciona inversamente com 
o risco de desenvolver diabetes tipo 2, devido à acção benéfica do álcool em biomarcadores da 
doença. Os vinhos são bebidas anti-diabéticas muito promissoras, não só pelo seu conteúdo 
alcoólico, mas também pela sua composição em compostos fenólicos. A investigação nesta área 
tem incidido no vinho tinto, existindo vários estudos sobre o seu potencial anti-diabético. Contudo 
não existem estudos em vinho branco, mesmo tendo sido reportado concentrações semelhantes 
ou maiores de ácidos hidroxicinâmicos, reconhecidos pelo seu potencial anti-hiperglicémico.   
O objectivo desta tese foi o de investigar o potencial anti-hiperglicémico dos vinhos brancos 
através de ensaios químicos e celulares. Deste modo, quatro vinhos foram caracterizados quanto 
à sua composição fenólica e à sua capacidade em inibir enzimas da digestão de hidratos de 
carbono e transportadores de glucose usando células Caco-2. 
Os resultados demonstraram que a composição fitoquímica variou grandemente entre os vinhos 
testados. O Aveleda Alvarinho apresentou uma concentração mais elevada e uma maior 
variedade em compostos fenólicos. Este vinho também demonstrou capacidade em inibir α-
amilase (IC50 199,5 mg EAG/L) e α-glucosidase e, em combinação com acarbose, aumentou a 
actividade desta. Foi demonstrada a contribuição do ácido gálico na inibição da α-glucosidase, 
com IC50 de 32,28 mg/L e, quando combinado com a acarbose, foi observado um efeito de 
sinergia. Resultados obtidos em células Caco-2 demonstraram a capacidade do Aveleda 
Alvarinho em inibir transportadores de glucose, SGLT1 e GLUT2 (IC50 79,5 mg EAG/L e 126,7 
mg EAG/L, respectivamente), sendo o efeito dependente da dose. A fração digerida do vinho 
demonstrou uma inibição ligeiramente superior dos transportadores de glucose, cujos efeitos se 
relacionam com os metabolitos fenólicos produzidos durante a digestão in vitro. 
Os resultados desta tese demonstraram que o vinho branco pode ser considerado uma fonte 
promissora de agentes naturais anti-hiperglicémicos. 
 
Palavras-Chave: Diabetes tipo 2; Vinho branco; Polifenóis; Transportadores SGLT1 e GLUT2; 
Enzimas da digestão de hidratos de carbono; Células Caco-2 
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1. Introduction 
 
1.1. Diabetes 
 
In the past decades, diabetes mellitus has become a worldwide health emergency. Data from the 
World Health Organization (WHO) shows that high blood glucose is the third leading risk factor 
for premature death globally, after high blood pressure and tobacco, and behind physical inactivity 
and obesity [1]. Nowadays, 415 million adults are estimated to suffer from this disease and 318 
million are at risk of developing diabetes from impaired glucose tolerance. Last year, 5 million 
adults have died from diabetes and these alarming numbers are predicted to increase to 642 
million adults in 2040 (Figure 1.1) [2].  
 
Figure 1.1: Worldwide diabetes prevalence (data from 2015) and projections for 2040. Adapted from IDF 
Diabetes Atlas, 7thedition [2]. 
 
Portugal is no exception and more than 1.3 million people with age between 20 – 79 years old 
suffer from this condition, and only 56% is properly diagnosed [3]. Diabetes was responsible for 
4% of the deaths in 2014, being the 5th cause of death in the country [3,4]. 
Diabetes is a group of metabolic disorders characterized by chronic hyperglycemia (high blood 
glucose levels) which causes long-term damage, dysfunction and failure of various organs. 
Deficient insulin action is the basis of all anomalies in carbohydrate, lipid and protein metabolism, 
and it can result from a deficient insulin secretion or from a reduced insulin response of the 
tissues. Frequently, both problems coexist in the same patient and it is not possible to determine 
which caused the hyperglycemia [5].  
The disease mostly manifests itself in one of two categories: type 1 diabetes mellitus (T1DM) or 
type 2 diabetes mellitus (T2DM), but there are other types such as gestational diabetes or other 
specific genetic defects that cause a form of diabetes. T1DM is an autoimmune disease that 
affects 5 – 10% of all diabetic cases. This type of diabetes is characterized by a cellular-mediated 
autoimmune destruction of the pancreatic β-cells, leading to an insulin deficiency with little or no 
secretion. Patients with T1DM, suffer or will suffer from ketoacidosis and are dependent of insulin 
intake.  
On the other hand, T2DM accounts for 90 – 95% of the cases and it is characterized by an insulin 
resistance. In these patients, autoimmune destruction of β-cells does not occur, and they usually 
2 
 
do not need insulin intake to survive. Because the hyperglycemia develops gradually, patients do 
not present the classic symptoms of diabetes at the first stages of the disease and do not get 
properly diagnosed early [5]. Type 2 diabetes is the result of genetic predisposition and 
environmental factors. In fact, epidemiological studies evidence that the worldwide diabetes 
epidemic faced by the 21th century society is due to lifestyle [6]. The lifestyle of developing 
societies has increased the prevalence of overweight and obesity, which resulted in the arising of 
the metabolic syndrome, a combination of pathological conditions including obesity, hypertension, 
dyslipidemia, insulin resistance, glucose intolerance and hyperglycemia (impaired glucose 
tolerance). The metabolic syndrome is related with an augmented risk of diabetes, as well as 
cardiovascular diseases, and several studies show that the syndrome usually predicts future 
diabetes [7,8]. There is no cure for diabetes, but the resulting complications can be ameliorated 
through diet and lifestyle modifications [6]. 
Nowadays, there is an increasing interest in the role of post-prandial hyperglycemia in T2DM. 
Repeated high post-prandial hyperglycemia is linked to several micro and macrovascular 
complications, being strongly associated with the risk of cardiovascular disease [9]. Over the 
years, multiple studies demonstrated that post-prandial hyperglycemia is linked to a severe 
progression of cardiovascular mortality risk and its treatment reduces the incidence of new 
cardiovascular events [10–12], as well as decreases the progression of several microvascular 
complications (such as renal failure and blindness due to retinopathy) . In consequence, 
prevention and management of post-prandial hyperglycemia has been a major issue in diabetic 
treatment. There are several therapeutic approaches available to control post-prandial 
hyperglycemia. Inhibitors of  glycoside hydrolases (GH) such as α-glucosidase and α-amylase 
are already recognized approaches [13], as well new targets like intestinal glucose transporters, 
SGLT1 and GLUT2 [14,15]. 
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1.2. Carbohydrate Digestion and Absorption in the Human Small Intestine 
 
Complex dietary carbohydrates cannot be directly absorbed by enterocytes in the small intestine 
epithelium. First of all, dietary carbohydrates have to be fully degraded by glycohydrolases. 
Salivary and pancreatic α-amylase cleave the complex carbohydrates, starch, in small 
oligosaccharides that are further digested by brush border α-glucosidases into monosaccharides. 
This cascade of catalytic reactions in the intestine occurs concomitantly [16]. Monosaccharides 
are then transported across the intestinal epithelium via specific transporters (SGLT1 and GLUT2 
transport glucose, and GLUT5 transports fructose) into the blood stream. It is in the first segments 
of the human intestine that there is a higher affinity for glucose molecules, and consequently a 
higher velocity of transport that ceases in the colon. The newly absorbed monosaccharides are 
then distributed to various organs and tissues, and take part in numerous metabolic pathways 
[17].  
 
1.2.1. Carbohydrate-Degrading Enzymes: α-Amylase and α-Glucosidase 
 
α-Amylases (EC 3.2.1.1) are GH 13 family enzymes, that catalyze the endohydrolysis of the α-
(1,4)-glycosidic bonds of starch. Starch, that constitutes 40 – 50% of the ingested carbohydrates 
in the Western diet, is a glucose polymer that consists of two different molecules: amylose, a 
linear chain of α-(1,4)-glucose linked units, and amylopectin, a branched molecule with a 
backbone of α-(1,4)- linked glucose and branches of α-(1,6)-glucose units. In mammalians, there 
are two isoforms of α-amylase: salivary, secreted by the parotid gland, and pancreatic, secreted 
by the pancreas into the small intestine [18]. Salivary α-amylase only has activity during food 
mastication in the mouth, because the low stomach pH promptly inactivates the enzyme [16].  On 
the other hand, pancreatic α-amylase is the first step of the carbohydrate digestion in the small 
intestine. It is a glycoprotein of 57 kDa that consists of 3 domains: A, B and C, and has 3 
functionally important sites: the active site, the calcium-biding site and the chloride-biding site. 
These functionally important sites are constituted by structural elements of domains A and B. 
Domain C appears to be an independent domain, with unknown function. The enzyme active site 
is located in the cleft between domains A and B and contains 5 subsites, with the catalytic site 
positioned at subsite 3. Glucose residues can bind to subsites 1 or 2, and cleavage occurs 
between the first and second or the second and third glucose residues. α-Amylase requires one 
calcium ion to stabilize the active site cleft, and chloride ions to maintain activity [18,19].   
The products of starch digestion by α-amylase are dextrins (maltose, maltotriose and branched 
oligosaccharides) and their further breakdown into monosaccharides will be accomplished by the 
intestinal brush border enzymes α-glucosidases [18].  
α-Glucosidases (EC 3.2.1.20) are a group of hydrolases from family GH 31 that catalyze the 
exohydrolysis of terminal, non-reducing α-(1,4)-glycosidic bonds of polysaccharides, releasing α-
D-glucose. These enzymes are commonly constituted by four major domains: an N-terminal 
domain, a (β/α)8-barrel catalytic domain and two C-terminal domains [20].  
In the small intestine there are four membrane bound glycohydrolases: trehalose, maltase-
glucoamylase, lactase and sucrase-isomaltase. Dextrins suffer further degradation by combined 
activity of maltase-glucoamylase and sucrase-isomaltase complexes, each containing two active 
sites. In humans, sucrase-isomaltase is more abundant than maltase-glucoamylase, accounting 
for about 10% of all brush border proteins, and therefore responsible for 80% of the maltase 
activity. Both subunits have maltase activity and this is also the only enzyme in the small intestine 
to have sucrase activity, essential to sucrose digestion. The catalytic mechanism and active site 
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architecture of most α-glucosidases occurs by very similar reaction mechanisms [16]. Briefly, the 
hydrolysis reaction of the glycosidic linkage occurs by cleavage of the bond between the anomeric 
carbon of the glycosyl residue and the glycosidic oxygen (Figure 1.2) [21].  
 
Figure 1.2:  Scheme of α-glucosidase hydrolytic reaction of an α-(1,4)-glycosidic bond. R is a reducing 
sugar residue. Adapted from Chiba, 1997 [21]. 
 
Since the activity of α-glucosidases is the final step before glucose absorption on the small 
intestine epithelium occurs, their inhibition is an effective way of decreasing post-prandial 
hyperglycemia peaks [22,23]. Acarbose, a pseudo-tetrasaccharide, is the first commercialized α-
glucosidase inhibitor and a very important anti-diabetic oral drug. The drug acts through a 
competitive and reversible inhibition of the brush border α-glucosidases and pancreatic α-
amylase, delaying the carbohydrate digestion, which reduces the rate of glucose absorption [24]. 
However, the use of α-glucosidase inhibitors as acarbose causes serious side-effects such as 
abdominal distention, meteorism, flatulence and diarrhea [24–26]. It has been proposed that this 
side effects are due to  a strong inhibition of the complex carbohydrates digestion, more precisely 
of an excessive pancreatic α-amylase inhibition, which allows the undigested carbohydrates to 
reach the colon, where abnormal fermentation results in intestinal gas, and consequently the side 
effects referred above [24,27,28]. Thus, it is necessary to search for alternative ways that can 
display the same α-glucosidase inhibitory activity without such side effects. Compounds from 
natural sources that display this anti-hyperglycemic bioactivity have been studied, yielding 
promising results [29]. 
 
1.2.2. Glucose Transport: SGLT1 and GLUT2 
 
Hydrophilic molecules, like sugars, cannot permeate freely across the lipid bilayer of the plasma 
membrane in eukaryotic cells. Transmembrane proteins from two different types are responsible 
for glucose transport in the organism: the sodium-coupled glucose cotransporters (SGLT) and the 
facilitated glucose transporters (GLUT). Both transporters belong to the sodium carrier gene 
superfamily (SLC), SGLT being transporters part of SLC5 gene family and GLUT transporters 
part of SLC2 family [30]. SGLT1 is a high-affinity and low-capacity transporter, responsible for 
glucose entrance in the enterocytes, while GLUT2 is a low-affinity but high-capacity transporter 
responsible for the transport of glucose and fructose into the blood and also into the enterocyte, 
at high luminal sugar concentrations [31]. 
SGLT1 is an integral membrane protein, constitutively expressed in the brush border enterocytes, 
responsible for the active transport of glucose. It can also transport galactose but with much lower 
affinity [30]. The SLC5 gene codes for proteins of 75 kDa, approximately. The structure of the 
transporter is not fully disclosed but it is already known that is a polytopic membrane protein, with 
two glucose binding sites on the C-termini, one on the extracellular face and another on the 
intracellular face of the protein. It is composed of 14 transmembrane helices, with the N- and C-
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termini facing the extracellular side of the plasma membrane. Glucose binds to the protein through 
hydrogen bonds, between the polar residues of the sugar and the polar side-chains of the binding 
site residue. The mechanism of transport is a symport, where the protein couples the transport of 
two sodium ions and one glucose molecule, against the glucose gradient, with an energy cost 
(Figure 1.3). Across the brush border membrane, a sodium electrochemical potential gradient is 
established, maintaining the driving force for glucose transport. It is the entrance of sodium ions 
with the glucose molecules into the cells and its transport into the blood by the Na/K-pump that 
maintains the gradient, providing the necessary  energy [32]. 
 
Figure 1.3: Model of Na/glucose cotransport by SGLT1. SGLT1 is negatively charged with a valence of -2, 
depicted in red. First of all, two sodium ions (yellow) bind to the transporter (1-2), producing a conformational 
change that allows the biding of one glucose molecule (2-3). Both the sodium ions and glucose are 
transported across the membrane (3-4) and, due to the low intracellular concentration of sodium, the sodium 
ions and glucose dissociate from the protein, entering the cell (4-5). Then, the protein binding sites re-
orientate from the inner to the external membrane surface (6-1). Taken from Wright et al., 2007 [32]. 
 
There has been an increasing interest in developing new approaches to regulate post-prandial 
glucose peaks by inhibiting the glucose absorption in the intestine through SGLT1 [17]. 
Nakazawa, in 1922, was the first to demonstrate that glucose transport could be reduced using a 
phenolic compound named phloridzin, a flavonoid glycoside mostly found in apples [33]. Decades 
later, in 1967, Alvarado demonstrated that the glucose transport reduction showed by Nakazawa 
was due to a potent competitive inhibition of SGLT1 in the intestinal brush border [34]. In recent 
years, phloridzin-like SGLT1 inhibitors have been developed by the pharmaceutical industry, and 
some are undergoing preclinical and clinical trials, however severe side effects due to the potent 
inhibition of the transporter can occur, such as diarrhea and other gastrointestinal problems [32].  
The two components of glucose absorption in the small intestine, one active and another “diffuse”, 
were established by Donhoffer in 1932 [35]. The importance of the “diffuse” component was 
showed by Madara & Pappenheimer in 1987, where the authors demonstrated that it accounts 
for approximately 75% of the glucose absorption but there was no consensus about its origin 
[36,37]. In the classical model of glucose absorption, GLUT2 was exclusively located at the 
basolateral membrane of the enterocytes and all glucose transport was managed by SGLT1. 
However, in recent years, it was discovered that GLUT2 could traffic to and from the apical 
membrane and was able to transport both fructose and glucose [31].  
Structurally, the GLUT proteins are composed of twelve hydrophobic transmembrane α-helices, 
with de C- and N-termini facing the cell cytoplasm [30]. They perform passive transport of glucose, 
facilitating the equilibrium of glucose and other sugars across the membranes. In the small 
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intestine epithelium, GLUT2 is constitutively expressed in the basolateral membrane of the 
enterocytes and it is responsible for the passive transport of glucose into the blood stream, 
although a fraction of the intracellular glucose seems to be transported into the blood by 
endosomes, as glucose-6-phosphate [32]. The activity of GLUT2 only depends on the glucose 
concentration and it is not saturated at physiologic glucose concentrations [30]. 
As mentioned above, GLUT2 is also a very important component of glucose transport between 
the intestinal lumen and the enterocyte’s cytoplasm [38].  
 
Figure 1.4: Intestinal glucose absorption model. (A) Before a meal, GLUT2 is present in the apical membrane 
at very low concentration and glucose transport is made only by SGLT1. Basolateral GLUT2 operates in the 
opposite direction, in order to supply glucose to the enterocytes so the cells can maintain their energy 
requirements. (B) After a meal, brush border α-glucosidases (H) hydrolyze polysaccharides and apical 
glucose concentration increases. Initially, glucose transport is made through SGLT1, increasing intracellular 
glucose concentration, which activates PKC βII. PKC βII then rapidly recruits and activate GLUT2 to the 
apical membrane from intracellular vesicles. At this point, GLUT2 is the major glucose absorption pathway. 
When the luminal glucose concentration declines, the signaling system is reversed and GLUT2 becomes 
inactivated and traffics away from the apical membrane. Figure taken from Kellett et al., 2005 [38]. 
Before a meal, the sugar concentration in the intestinal lumen is very low, and the only active 
transporter in the brush border is SGLT1. GLUT2 is present at a very low concentration or even 
absent, to minimize glucose escape from the mucosa (Figure 1.4 A). After a meal, the 
concentration of sugars at the brush border is higher and α-glucosidases degrade 
oligosaccharides into glucose, augmenting the luminal glucose concentration. SGLT1 transports 
glucose until saturation is reached. The increasing glucose concentration at the lumen activates 
PKC βII which recruits GLUT2 into the apical enterocyte membrane, allowing glucose to enter the 
cell by facilitated transport (Figure 1.4 B). Thus, GLUT2 is responsible for the major path of 
absorption at high luminal glucose conditions. The transporter response to glucose is 
concentration-dependent and cooperative, because GLUT2 activation and protein concentration 
in the apical membrane increase with glucose concentration [31,38].   
Apical GLUT2 recruitment is strongly linked to diet. Increased glucose transport by apical GLUT2 
might be a factor in repeated insulin spikes, which contributes to insulin resistance, obesity and 
type 2 diabetes. Thus, apical GLUT2 is a potent therapeutic target in type 2 diabetes patients. 
Modulation of glucose absorption through dietary manipulation can be an important approach to 
reduce post-prandial glucose peaks [38]. 
 
B     After a meal A     Before a meal 
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1.3. Natural Compounds and Type 2 Diabetes  
 
Plants were the basis of sophisticated traditional medicine, used for the treatment of a wide 
spectrum of diseases, with the earliest records dating from 2600 BCE, documenting the uses of 
1000 plant-derived substances in Mesopotamia. Throughout the years, natural compounds have 
been the source of most active principles and very important lead compounds in the discovery 
and development of new drugs. These compounds are of very high interest for drug development 
not only because of their structural diversity, but also because often they possess selective and 
specific biological activities based on mechanisms of action. It is proposed that the bioactivity of 
natural products arises from the fact that all natural compounds have receptor-binding activity in 
vivo, although finding the receptor to which a given compound binds is a challenge. Even though 
the interest in the investigation of bioactive compounds from plants, only 6% of the higher plants 
have been pharmacologically studied and 15% evaluated regarding their phytochemical 
composition [39,40]. Nowadays, screening of natural compounds by pharmaceutical companies 
has decreased because of the difficulties of access and supply, the complexities of the chemistry 
of natural products and the slowness of working with this products, which is counter-productive 
since these compounds were the source for a considerable number of important drugs that are 
presently on the market [39,40]. 
Another approach that many pharmaceutical and biotechnological companies have to take 
advantage of these natural bioactive compounds is the development of nutraceuticals and 
functional foods. The term nutraceutical was first defined by Stephen DeFelice in 1979 as a “food, 
or parts of food, that provide medical or health benefits, including the prevention and treatment of 
disease” [42],. A nutraceutical is a diet supplement that contains a concentrated form of a bioactive 
compound, presented in a non-food matrix, in dosages that exceed those that could be obtained 
from normal food, while a functional food is a food that when regularly consumed exerts a specific 
beneficial effect beyond its nutritional properties, the effect of which has to be scientifically proven 
[43]. 
 
Functional foods and nutraceuticals make the interface between pharmaceuticals, that are 
traditionally utilized to treat or alleviate symptoms of diseases, and nutrition, of which the first aim 
is to provide the body with an optimal balance of nutrients needed for good health, thus preventing 
diseases (Figure 1.5). Since today’s chronic diseases have a multifactorial origin, a treatment 
approach complementing pharmaceuticals and nutrition is the most successful [44].  
These health-promoting products, such as nutraceuticals and functional foods, usually contain 
bioactive compounds that are constituents of plant-derived foods that present health-promoting 
Figure 1.5: Interface between pharmaceuticals and nutrition. Adapted from Eussen, S. et al., 2011 [44]. 
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effects. Part of the capacity that some plant-derived foods have to reduce the risk of chronic 
diseases has been associated to phytochemicals. Phytochemicals are non-nutrient secondary 
metabolites that exist in fruits and vegetables and have a low potency when compared to 
pharmaceutical compounds, but when ingested regularly have a noticeable long-term 
physiological effect.  These bioactive constituents can be incorporated into the products as food 
extracts or phytochemical enriched extracts, to which a given beneficial physiological function has 
been attributed. The most common phytochemicals found in these products are polyphenols such 
as anthocyanins, flavonols, stilbenes and hydroxycinnamic acids, but glucosinolates and 
terpenoids are found often as well [43]. 
Dietary polyphenols can be found in vegetables (broccoli, onion, cabbage), fruits (grapes, apples, 
cherries and a wide variety of berries), legumes (soybeans), cereals, plant derived beverages 
(tea, coffee, wine) and chocolate [45]. There are over 8000 plant phenolic compounds identified 
and they have diverse and important physiological and morphological functions, such as 
phytoalexins, antifeedants, pigmentation, protection against UV light and antioxidants [46]. 
Phenolic compounds are characterized by having one (monophenolic) or more than one aromatic 
rings (polyphenolic), bearing at least one hydroxyl group. They can have from a simple structure, 
a simple phenolic acid or alcohol, to a complex high molecular mass polymer, and usually are 
conjugated with sugars and organic acids [46,47]. 
 
 
 
 
 
 
 
 
 
Figure 1.6: Classification and chemical structures of phenolic compounds reported in the literature as having 
health benefits. Adapted from Kim et al., 2016 [48]. 
According to the number of phenol rings and the structural elements connecting the rings, 
polyphenols can be divided into classes: flavonoids, phenolic acids, phenylethanol derivates, 
tannins, stilbenes, lignans and coumarins (Figure 1.6). The diversity of structures and the different 
characteristics of the phenolic compounds originates the different recognized bioactivities [45–
47]. 
In recent years, it has been observed that phytochemical extracts or plant-derived foods produce 
a different effect than the pure isolated bioactive compounds [49].  Polyphenols can interact 
additively, synergistically or antagonistically with other phenols and other food components, as 
well as with drugs, both from natural or synthetic origin [50]. Several studies on different medical 
conditions have demonstrated the increased efficacy of the co-administration of pharmaceutical 
drugs combined with polyphenols, as well as different combinations of polyphenols, and their 
value as therapeutic alternatives. These therapeutic combinations present diminished side effects 
and lower toxicity than increased drug concentrations [51–56].  
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The consumption of a diet abundant in plant-derived products, rich in polyphenols, has been 
inversely correlated with the incidence and prevalence of type 2 diabetes. Epidemiological and 
clinical studies have demonstrated that T2DM can be prevented and the symptoms ameliorated 
by lifestyle modifications such as increased physical activity, weight loss and a balanced diet rich 
in fruits and vegetables. This fact has raised interest in discovering which type of polyphenols are 
associated with the beneficial effects and which are their mechanisms of action [48,57,58]. 
Summarized in table 1.1 are several phenolic compounds that have been shown to have an anti-
diabetic role, mostly by producing an anti-hyperglycemic effect, and the underlying mechanism of 
action.  
Table 1.1: Reported anti-hyperglycemic effect of different types of phenolic compounds. ↑ increase; ↓ 
decrease. 
 
 Phenolic 
Compound 
Anti-Diabetic Effect In vivo In vitro Reference 
Flavonols 
Catechin 
↓ α-Glucosidase activity, ↓ Intestinal 
glucose absorption (SGLT1)   
[59–61] 
Epicatechin 
↓ Intestinal glucose absorption 
(SGLT1), Protection of β cells in isles 
or pancreas, ↑ Insulin secretion 
  [61–63] 
Quercetin 
↓ α-Amylase activity, ↓ α-Glucosidase 
activity, ↓ Intestinal glucose 
absorption (GLUT2 and SGLT1) 
  [61,64–66] 
Cyanidin ↓ α-Amylase activity   [64] 
Phenolic 
Acids 
Caffeic Acid 
↓ α-Amylase activity, ↓ α-Glucosidase 
activity, ↓ Intestinal glucose 
absorption (SGLT1) 
  [59,60,67–69] 
Chlorogenic 
Acid 
↓ α-Amylase activity, ↓ α-Glucosidase 
activity, ↓ Intestinal glucose 
absorption (SGLT1 and GLUT2) 
  [59,60,67,70–73] 
p-Coumaric 
Acid 
↓ α-Glucosidase activity, ↓ Intestinal 
glucose absorption (SGLT1 and 
GLUT2) 
  [68,73] 
Ferulic Acid 
↓ α-Glucosidase activity, ↓ Intestinal 
glucose absorption (SGLT1), ↑ 
insulin secretion, Induction of hepatic 
glucokinase activity 
  [60,68,69,72,74,75] 
Gallic Acid ↓ α-Glucosidase activity   [68] 
Tannins Tannic Acid 
↓ α-Amylase activity, ↓ α-Glucosidase 
activity, ↓ Intestinal glucose 
absorption (SGLT1) 
  [60,68,70] 
Stilbenes 
Resveratrol 
↓ α-Glucosidase activity, ↓ Intestinal 
glucose absorption (SGLT1) 
  [76,77] 
ε-Viniferin 
↓ Intestinal glucose absorption 
(SGLT1) 
  [77] 
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1.4. White Wine and Health 
 
White wine is one of the 100 richest dietary sources of polyphenols, which have been linked to 
produce improvement on health [78,79]. For many years, the so called “French Paradox” has 
been studied: despite a high consumption of saturated fats, the mortality in France from 
cardiovascular events is low, in comparison with other countries with the same eating habits. 
Various epidemiological studies have proposed that the regular and moderate consumption of 
wine is responsible for these beneficial effects on health, not only in cardiovascular diseases, but 
also in lowering the declining of cognitive function in neurological diseases, lowering the risk of 
developing diabetes mellitus and cardiometabolic complications in diabetic patients (Figure 1.7) 
[78,79,80]. The biological effect of wine is mostly due to its wide variety of phenolic compounds, 
therefore having a wide range of potential biological targets [79].  
 
 
Figure 1.7: Biological effects produced by the consumption of wine described in the literature. Abbreviations: 
ROS, reactive oxygen species; NO, nitric oxide; LDL, low-density lipoprotein cholesterol; HDL, high-density 
lipoprotein cholesterol. Adapted from Artero, et al., 2015 [79]. 
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1.4.1. Phytochemical Composition of White Wine 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
White wine is a mixture of different components: water, ethanol, glycerol, polysaccharides, 
organic acids and phenolic compounds [79]. Non-volatile phenolic compounds are intrinsic 
components of grapes and their derivatives, such as wine. The different phenolic composition 
between different wines is due to the fact that phenolic composition is very dependent on the 
grape variety and maturity, environmental factors, as well fermenting and aging conditions [82].  
Wine phenolics are usually divided into two categories: flavonoids and non-flavonoids. Flavonoids 
are the major polyphenolic class in red wines and exist in white wines in a considerably lower 
concentration. This happens because red wine production involves maceration and flavonoids 
are extracted during the process from skin and other grape components, while in white wine 
production the maceration step is avoided. These phenolic compounds mostly occur in wine as 
flavonols, flavones and anthocyanidins [79,83].  
Non-flavonoid phenolic compounds are mostly found as hydroxycinnamic acids, hydroxybenzoic 
acids, stilbenes and hydrolysable tannins. Hydroxycinnamic acids are the major class of phenolic 
compounds in white wine. In grapes they are the third most abundant class of phenolics, existing 
as esters of tartaric acid - caftaric, coutaric and fertaric acids. As wine is an aqueous acidic 
solution, the esters are hydrolyzed releasing the simple acids – caffeic, p-coumaric and ferulic 
acids- existing there in both forms. Hydroxybenzoic acids are not as common in wine as 
hydroxycinnamic acids but several have been already identified. Gallic acid is fairly abundant as 
it is the precursor of all the hydrolysable tannins. Hydrolysable tannins and stilbenes are another 
minor classes of phenolics in white wine. Hydrolysable tannins are complex polyphenols that can 
be found as gallotannins and ellagitannins, which come from aging in oak barrels. Resveratrol is 
the most mentioned and abundant stilbene present in wine, forming oligomeric forms known as 
viniferins [82–84]. Throughout the years, the health improvement effects of wine have been 
attributed to the presence of resveratrol, mostly regarding its presence in red wine and its 
beneficial effects in cardiovascular diseases [79,85,86]. However, studies have brought evidence 
that the beneficial effects of wine are in reality due to other phenolic acids and not only resveratrol 
[87].  
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1.4.2. White Wine and Diabetes 
 
Several of phenolic compounds that exist in white wine have already been reported to present a 
promising effect in type 2 diabetes by diminishing the post-prandial glucose peak, producing an 
anti-hyperglycemic activity. In fact, epidemiological and clinical studies have reported that white 
wine can lower glucose plasma concentration and lower the risk of developing type 2 diabetes, 
while not presenting any adverse effects in diabetes type 2 patients. The studies are summarized 
in table 1.2. 
Table 1.2: Summary of cohort studies related with white wine consumption and the reduced risk of type 2 
diabetes. ND, not defined  
Subjects Study/Method Dose/Duration Effects/Results Reference 
18 patients 
with T2DM 
Randomized 
controlled trial 
Dosage: 240 mL 
Duration: 30 days 
White wine moderate 
consumption did not present 
any harmful effect on patients 
and lowered fasting serum 
insulin. 
Bantle, et al., 2007 [88] 
224 
patients 
with T2DM 
Randomized 
controlled trial 
Dosage: 150 mL 
Duration: 2 years 
Observed benefit from both 
red and white wine in glycemic 
control. No adverse effects 
observed from wine intake. 
Gepner, et al., 2015 
[89] 
36 527 
adults 
Observational 
study. Dietary 
assessment by 
questionnaire 
Dosage: ND 
Duration: 4 years 
Incident cases of T2DM were 
identified. Wine, both red and 
white, consumption was 
associated with a lower risk of 
developing T2DM in women. 
Hodge, et al., 2006 
[90] 
20 healthy 
males 
Randomized 
controlled trial 
Dosage: 400 mL 
Duration: 2 weeks 
Consumption of red and white 
wine resulted in a reduction in 
plasma glucose concentration. 
Lavy, et al., 1994 
[91] 
 
In recent years, studies with white wine pomace and other derivatives have brought evidence that 
phenolic compounds from white grapes can modulate the carbohydrate digestion by α-amylase 
and α-glucosidase inhibition [92,93]. There is preliminary studies showing that white wine 
compounds are able to inhibit these enzymes, however these assays are mainly carried out with 
α-glucosidase and α-amylase derived from yeast [94]. With respect to glucose transport across 
the small intestine epithelium, there are studies including phenolic compounds that are known to 
exist in white wine, demonstrating their potential in modulating glucose absorption [61,65,77]. 
However, there are no studies assessing the effect of white wine in intestinal glucose absorption 
in this context.  
White wine is a promising study model for the modulation of carbohydrate digestion and 
absorption in the small intestine, which can have a beneficial effect in type 2 diabetes patients. 
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1.5. Aim of the Thesis 
 
Wine contains phenolic compounds recognized for their antioxidant and anti-hyperglycemic 
proprieties. Regarding diabetes, particular attention has been given to red wine due to its high 
polyphenolic concentration. On the contrary, few studies have been done with white wine. 
However, given its rich phytochemical composition in phenolic acids with recognized anti-
hyperglycemic activity, white wine is a promising candidate for study. 
The aim of this thesis is to explore the anti-hyperglycemic potential of white wines. 
In order to achieve the proposed goals, the work was divided in four tasks, giving rise to two parts, 
and it is schematically represented in Figure 1.8: 
 
Figure 1.8: Structure of the thesis. 
In the first part of the thesis the phytochemical characterization of the four white wine samples 
was carried out. The enzymatic assays were also performed in this part: α-amylase inhibition 
dose-response curves were done in order to determine the IC50 of all samples and α-glucosidase 
inhibition assessment was also done for the four samples. Synergy studies between wine and 
acarbose were pursued, as well as identification of the possible bioactive compounds responsible 
for the observed effect and its synergy with acarbose. The results obtained in the first part of the 
thesis allowed the selection of the most promising white wine to pursue the remaining work. The 
second part focused on the SGLT1 and GLUT2 inhibition using Caco-2 cells as a model for small 
intestinal epithelium, with both in vitro digested and dealcoholized white wine. Dose-response 
curves were performed for both samples and IC50 values determined, as well as screening for 
identification of bioactive compounds that display glucose absorption inhibitory potential.  
This work follows on the project "White Wine and Health" funded by Aveleda, where the 
phytochemical composition of white wines was evaluated, as well its antioxidant potential. 
Preliminary results on enzymatic studies prompted interest in exploring the anti-hyperglycemic 
potentialities of white wine.  
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2. Experimental Procedure 
 
2.1. Wine Samples 
 
Five different white wines were used in this work, four from Aveleda (Douro) and one from 
Portalegre Wine Cooperative (Alentejo), different in its origin and in the grape varieties utilized in 
its manufacture. The wines tested from Aveleda were Quinta da Aveleda (2011, Loureiro and 
Alvarinho grape varieties, 11% alcohol volume), Aveleda Douro Doc (2011, Gouveio, Malvasia 
and Moscatel grape varieties, 12% alcohol volume) and Aveleda Alvarinho (2011 and 2014, 
Alvarinho grape varieties, 12% alcohol volume). From Portalegre Wine Cooperative, Conventual 
(2011, Arinto, Fernão Pires and Roupeiro grape varieties, 13.5% alcohol volume) was the only 
wine tested. 
 
2.1.1. Phenolic Fraction 
 
White wine has a small percentage of endogenous sugars, which can interfere with α-glucosidase 
assays.  
Polyphenolic rich fractions, devoid of endogenous sugars, were obtained by solid phase 
extraction (SPE) as described by Manzano et al., with some modifications [73]. SPE cartridges 
(Supelclean™ LC-18 SPE Tubes, Supelco) were conditioned with 4 mL of white wine and washed 
with 10 mL of Milli-Q water, in order to remove the endogenous sugars. The polyphenolic rich 
fraction was eluted with 10 mL of methanol and concentrated in a rotary evaporator at 40°C under 
reduced pressure.  
 
2.2. Phytochemical Characterization 
 
2.2.1. Total Phenolic Content by the Folin-Ciocalteau Method 
 
Quantitative determination of the polyphenolic concentration in white wines was performed 
according to the Folin-Ciocalteau colorimetric method [95], as previously described by Serra, et 
al. [96]. In a 96-well microplate, 3 µL of wine samples were added to 237 µL of distilled water and 
oxidized with 15 µL of Folin-Ciocalteau reagent. The reaction was neutralized with 45 µL of 
sodium carbonate (Na2CO3). After a 30 minutes incubation at 37 °C, the absorbance of the 
samples was measured in a microplate spectrophotometer (Spark® 10M, Tecan, Switzerland) at 
765 nm. Gallic acid (Fluka, Germany) was used as an external standard for the calibration curve 
(0 – 800 mg/L), and the results were expressed as means of triplicates (mg of gallic acid 
equivalents per liter of wine – mg GAE/L) ± standard deviation.  
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2.2.2. Polyphenolic Analysis by HPLC 
 
Qualitative and quantitative profiles of polyphenols present in the samples were determined using 
HPLC-DAD by the Analytical Group of iBET (Oeiras, Portugal) coordinated by Dr. Rosário Bronze. 
The system used was a Thermo Finnigan (Surveyor model) equipped with an autosampler, pump 
and photodiode-array detector (PDA). Chromatographic separation of compounds was carried 
out on a Lichrocart RP-18 column (250 x 4 mm, particle size 5 µm, Merck) and a Manu-cart® RP-
18 pre-column in a thermostated oven at 35°C. The photodiode array detector was programmed 
for scanning between 192 and 798 nm at a speed of 1Hz with a bandwidth of 5 nm. The detection 
was monitored using three individual channels, 280, 320 and 360 nm, at a speed of 10Hz with a 
bandwidth of 11 nm. The injection volume applied was 20 µL. Chromatographic separation of 
phenolic compounds was carried out with solvent A – acetonitrile, water and formic acid 
(90:9.5:0.5 v/v/v) – and solvent B – water and formic acid (99.5:0.5 v/v) – under the following 
conditions: linear gradient starting at 94.4 – 83.3% solvent B in 15 minutes, 83.3-77.8% in 20 
minutes, isocratic for 10 minutes, 77.8-66.70% solvent B in 55 minutes, 66.70 – 44.40% in 80 
minutes, 44.0 – 0% in 120 minutes, isocratic for 15 minutes, 0 – 94.40 % in 140 minutes and 
isocratic for 20 minutes. The auto sampler’s temperature was set at 12°C. The data acquisition 
system used was the Chromquest (version 4.0, Thermo Finnigan-Surveyor, USA). 
Identification of compounds was achieved by comparison of retention times and spectra with pure 
standards within that range. Calibration curves were constructed with gallic acid, neochlorogenic 
acid, catechin, epicatechin, caffeic acid, p-coumaric acid, ferulic acid and resveratrol (0 – 50 ppm), 
as external standards, and results were expressed as milligrams per liter of white wine (mg/L). 
 
2.2.3. Polyphenolic Analysis by HPLC-MS 
 
Analyses by HPLC - MS were performed by the Analytical Group of iBET (Oeiras, Portugal) 
coordinated by Dr. Rosário Bronze. Identification and quantification of the compounds present in 
white wines was performed by reverse phase LC (Waters Alliance 2695 Separation Module, 
Waters®) followed by negative ion electrospray ionization with MS/MS (MicroMAss 
Quattromicro® API, Waters®). 
 
2.3. Enzymatic Assays 
 
2.3.1. α-Amylase Inhibition Assay 
 
The α- amylase (EC 3.2.1.1) inhibitory capacity of white wines was assessed through the iodine-
starch colorimetric assay, as described by Al-Dabbas et al. [97]. Briefly, 60 µL of white wine, in a 
range of different concentrations, were incubated with 200 µL of a starch solution (400 µg/mL) at 
37°C for 5 minutes. Then, 20 µL of a 50 µg/mL solution of α-amylase from porcine pancreas 
(Sigma Chemical Co., USA) prepared in PBS (Sigma-Aldrich, USA) were added to the reaction 
mixture, as well as 20 µL of 0.01 M PBS. The mixture was incubated at 37°C for 7.5 minutes. 
Finally, 200 µL of 0.01 M iodine solution and 1 mL of distilled water were added. The reaction of 
the iodine solution with the starch produces a purple-black color, whose absorbance was recorded 
at 660 nm in a spectrophotometer (Genesys10uv, Thermo Spectronic, New York, USA). The 
negative control of the samples was performed without addition of enzyme (20 µL of 0.01 M PBS) 
and a solution of 0.02 mg/mL of acarbose (Glucobay® 50, acarbose 50 mg, Bayer, Germany) 
was used as a positive control of the reaction.  
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The inhibition (%) was calculated according to equation 1:  
Inhibition (%) =  
Abs blank660 nm −(Abs sample without enzyme660 nm−Abs sample with enzyme660 nm)
Abs blank660 nm
  Equation (1) 
 
The wine concentration that reduces α-amylase activity by 50% (IC50) was determined for each 
sample. Dose-response curves of α-amylase inhibition (%) versus wine concentration (mg GAE/L) 
were plotted, and the IC50 values of the tested wine samples were determined using non-linear 
regression with GraphPad Prism® (version 6.01, GraphPad Software Inc., USA). 
All assays were carried out as triplicates and the results expressed as mean of % inhibition ± 
standard deviation.  
 
2.3.2. α-Glucosidase Inhibition Assay 
 
α- Glucosidase (EC 3.2.1.20) inhibition by white wines was determined according to the method 
described by Mai et al. [98] with some modifications. The enzymes were extracted from rat 
intestinal acetone powder (Sigma Chemical Co., USA), source of mammalian α-glucosidases. A 
5 mg/mL solution of rat intestinal acetone powder was prepared in 0.1 M maleate buffer at pH 
6.9, homogenized and centrifuged (Mikro 220R, Hettich, Germany) at 5600x g during 15 minutes, 
at 4°C. The supernatant collected was diluted to a 1:2 ratio in 0.1 M maleate buffer pH 6.9. 
Twenty-five microliters of sample were preincubated with 50 µL of an α-glucosidase solution for 
15 minutes at 37°C in a 96-well microplate. Then, 50 µL of 2 mM 4-Nitrophenyl α-D-
glucopyranoside (Sigma-Aldrich, USA) in 0.01 M PBS (pH 6.9) were added to the mixture in order 
to start the reaction, and the absorbance was read at 405 nm in a microplate spectrophotometer 
(Spark® 10M, Tecan, Switzerland). The reaction mixture was further incubated at 37°C for 30 
minutes and the reaction stopped by adding 175 µL of 1 M Na2CO3. The of amount p-nitrophenol 
released from the p-NPG at 405 nm was used to determine the enzyme activity.       
For each sample at each tested concentration, a negative control was performed by adding 50 
µL of 0.1 M maleate buffer (pH 6.9) instead of α-glucosidase. Therefore, any interference of the 
sample color in the absorbance recorded at 405 nm could be eliminated. 
In order to eliminate the interferences of the reaction mixture components, all values recorded 
after 30 minutes incubation were corrected by subtracting the absorbance values at 405 nm 
recorded after the addition of p-NPG. 
The inhibition (%) was calculated according equation 2:  
Inhibition (%) =  
Abs blank405 nm −(Abs sample without enzyme405 nm−Abs sample with enzyme405 nm)
Abs blank405 nm
  Equation (2) 
 
The IC50 of acarbose and gallic acid were determined by plotting the dose-response curve of α-
glucosidase inhibition (%) versus concentration (mg/L). The IC50 values were determined using 
non-linear regression with GraphPad Prism® (version 6.01, GraphPad Software Inc., USA). 
The quantitative analysis of the dose-effect relationship between the combined effects of 
acarbose and gallic acid on the α-glucosidase inhibition was performed using the Chou-Talalay 
method [99]. Synergism, addition and antagonism were quantified through the calculation of the 
Combination Index (CI) using CompuSyn (Version 1.0, 2004, Combo Syn Inc., USA). 
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All assays were carried out at least as duplicates and the results expressed as mean of % 
inhibition ± standard deviation. Statistical significance was established by ANOVA using 
GraphPad Prism® (version 6.01, GraphPad Software Inc., USA). 
 
2.4. In vitro Digestion 
 
An in vitro digestion procedure, as described by Minekus et al. [100], was used to evaluate the 
transformation that white wine polyphenols suffer throughout the gastrointestinal tract. The 
procedure simulates digestion on the upper digestive tract and is carried out through three 
phases: oral phase, gastric phase and small intestinal phase.  
 
Oral Phase 
In the oral phase, 5 mL of white wine were added to 4 mL of Simulated Salivary Fluid (KCl, 15.09 
mM; KH2PO4, 1.35 mM; NaHCO3, 13.68 mM; MgCl2(H2O)6, 0.15 mM; NH4(CO3)2, 0.06 mM; 
CaCl2(H2O)2, 1.5 mM; HCl, 1.1 mM; pH 7). The pH was adjusted to 7 by adding 6 M NaOH, and 
the final volume of the mixture brought to 10 mL by addition of Milli-Q water. The mixture was 
allowed to incubate for 2 minutes at 37°C, under constant agitation. Since the test sample was 
liquid, simulated mastication or addition of human salivary α-amylase (EC 3.2.1.1) were not 
required.  
Gastric Phase 
The mixture resulting from the oral phase was carried out to the gastric phase by adding 8 mL of 
Simulated Gastric Fluid (KCl, 6.9 mM; KH2PO4, 0.9 mM; NaHCO3, 25 mM; NaCl, 47.2 mM; 
MgCl2(H2O)6, 0.12 mM; NH4(CO3)2, 0.5 mM; CaCl2(H2O)2, 0.15 mM; HCl, 15.6 mM; pH 3) and 1 
mL of pepsin (EC 3.4.23.1) from porcine gastric mucosa (Sigma, USA). One molar HCl was added 
until pH 3 and water was added to bring the mixture to a final volume of 20 mL. The gastric 
digestion step was conducted for 2 hours at 37°C, under constant agitation.  
Small Intestine Phase  
Before the small intestine phase was started, a 5 mL sample of the gastric digestion mixture were 
collected to HPLC analysis. The enzymatic reaction was stopped by the addition of 6 M NaOH 
and the sample stored at -20°C. To the remaining volume of gastric digestion mixture were added 
7 mL of Simulated Intestinal Fluid (KCl, 6.8 mM; KH2PO4, 0.8 mM; NaHCO3, 85 mM; NaCl, 38.4 
mM; MgCl2(H2O)6, 0.33 mM; CaCl2(H2O)2, 0.6 mM; HCl, 8.4 mM; pH 7), 1.88 mL of bile extract 
porcine (Sigma, USA) and 5 mL pancreatin from porcine pancreas (Sigma-Aldrich, USA). Finally, 
the mixture was brought to pH 7 by addition of 6 M NaOH and Milli-Q water added to yield a final 
volume of 30 mL. Incubation of the final intestinal digestion mixture occurred for 2 hours at 37°C, 
under constant agitation.  
Further enzymatic action on the intestinal digestion sample was stopped through the addition of 
10 µL of Pefabloc® (Sigma-Aldrich, USA) per milliliter of digested sample. The mixture was 
transferred to Amicon® Ultra-4 Centrifugal Filter Units (Merck Millipore, Germany) and centrifuged 
(Mikro 220R, Hettich, Germany) at the maximal velocity, for 40 minutes. All collected samples 
were stored at -20°C until further use. 
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2.5. Cell-Based Assays 
 
2.5.1. Cell Culture 
 
Human colon adenocarcinoma Caco-2 cells were obtained from Deutsche Sammlung von 
Microorganismen und Zellkulturen (Braunschweig, Germany) and grown in RPMI 1640 medium, 
supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (PS). The stock 
cells were maintained as monolayers in 175 cm2 culture flasks and incubated at 37ºC in a 5% 
CO2 humidified atmosphere. The cultured cells were split once or twice a week and their growth 
monitored daily. Cell culture medium and supplements were obtained from Invitrogen (Gibco, 
Invitrogen Corporation, Paisley, UK).  
 
2.5.2. Cytotoxicity Assay 
 
Cytotoxicity evaluation for all samples was performed using differentiated Caco-2 cells. Caco-2 
cells are utilized as a model of the intestinal barrier because in long –term culture the cells suffer 
a spontaneous differentiation and polarization that leads to the formation of monolayers, 
expressing several functional and morphologic characteristics of mature enterocytes [101]. 
The procedure was done as described by Serra et al. [102] with some modifications. Cells were 
seeded in 96-well culture plates at a density of 2 x 104 cells/well, and the medium changed every 
48 hours. The cells were allowed to grow for 8 days, until confluence and differentiation were 
reached. White wine samples in appropriate dilutions, were diluted in culture medium (RPMI 1640, 
supplemented with 0.5% FBS) and added to the wells. Control cells were carried out with only 
culture medium or in a mixture of the tested samples solvent and medium. Cells and white wine 
samples were incubated for 1 and 4 hours in a 5% CO2 humidified atmosphere at 37ºC. 
Cytotoxicity determination was performed using Cell Titter® AQueous One Solution Cell 
Proliferation Assay (Promega, USA). The viability reagent was diluted according to the 
manufacturer information and incubated for 3 hours at 37°C under a 5% CO2 humidified 
atmosphere. After incubation, absorbance was measured in a spectrophotometer (Spark® 10M, 
Tecan, Switzerland) at 490 nm. Results were expressed as viability, the percentage of living cells 
determined relatively to the control, and presented as means of triplicates ± standard deviation. 
Dose-response curves were plotted and IC50 values calculated using non-linear regression, with 
GraphPad Prism® (version 6.01, GraphPad Software Inc., USA).  
 
2.5.3. Glucose Transport Measurements 
 
Culture of Caco-2 cells on permeable supports allowed the cells to grow in an environment that 
better reproduces the steric conditions existing in the human small intestine, whereby, nutrients 
and ions have access to both sides of the monolayer, the apical side (intestinal lumen) and the 
basolateral side (blood stream). These conditions lead to a morphological and functional 
improved differentiation, such as the establishment of a trans-epithelial electrical resistance 
(TEER), that was used to monitor the integrity of the cell monolayer. After 20 days in culture, 
Caco-2 cells express several features of the mature small intestine enterocyte. Expression of 
sugar transporters (SGLT1, GLUT2 and GLUT5), as well amino acids, vitamins and other 
nutrients, have been identified [101]. 
Caco-2 cells were seeded at 2.24 x 105 cells/mL density in 12 mm Transwell® polycarbonate 
inserts (Corning®, USA). The cells were allowed to reach confluence and were cultured for 21 
days under a 5% CO2 humidified atmosphere, at 37°C. The medium (RPMI 1640, 10% FBS and 
1% PS) was changed every 48 hours and the differentiation and integrity of the cell monolayer 
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assessed by TEER measurements. Inserts with TEER values exceeding 500 Ω were used in the 
experiments. 
Glucose transport measurements were determined according to the method described by 
Manzano et al. [73]. After 21 days of culture, cell medium was carefully discarded from apical and 
basal compartments and both compartments were washed twice with HEPES buffer solution A 
(HEPES, 20 mM; NaCl, 137 mM; KCl, 4.7 mM; MgSO4, 1.2; CaCl2, 1.8 mM; pH 7.4). Then, HEPES 
buffer solution A was discarded from the apical compartment and 500 µL of the test solutions 
dissolved in solution B (HEPES buffer solution A containing 1 mM glucose (Sigma, USA) and D-
[U-14C] glucose 0.5 µCi/mL) were added. The basal solutions were HEPES buffer solution A. The 
plate was incubated at 37°C under a 5% CO2 humidified atmosphere for 30 minutes. After the 
incubation, TEER measurements were taken in order to assess the integrity of the cell monolayers 
and solutions from both compartments were collected for scintillation counting. Membranes were 
washed twice with ice-cold 0.01 M PBS (Sigma-Aldrich, USA) to stop glucose uptake. Afterwards, 
cells were lysed by the addition of 500 µL of 0.1 M NaOH. Cells and base were incubated for 10 
minutes at room temperature and aliquots were removed for scintillation counting and protein 
quantification.  
The detection of the radio-labeled D-[U-14C] glucose was performed by addition of 400 µL of each 
collected sample to 4 mL of scintillation liquid (Ecoscint XR, National Diagnostics, USA) and 
samples were analyzed by scintillation counting using a Beckman LS 6500 Scintillation System 
(Beckman Coulter Inc., USA).  
The same protocol was followed to investigate the glucose transport under sodium-free 
conditions. The HEPES buffer solution A was modified so that the 137 mM NaCl were replaced 
with 137 mM KCl and adjusted to pH 7.4 with 10 M KOH. 
The amount of glucose (mM) in each compartment was determined using glucose as an external 
standard for the calibration curve (0 – 1 mM). Dose-response curves were plotted and IC50 values 
calculated using non-linear regression with GraphPad Prism® (version 6.01, GraphPad Software 
Inc., USA).  
The results were expressed as means of at least duplicates of mg of glucose ± standard deviation. 
 
2.5.4. Total Protein Content  
 
Total concentration of protein extracted from Transwell® inserts was determined by the Bradford 
method [103]. In a 96-well microplate 5 µL of each sample were added to 250 µL of Bradford 
reagent (Sigma-Aldrich, USA). The plate was allowed to incubate at room temperature for 30 
minutes in an orbital microplate shaker (Orbit™ P4 Digital Shaker, Labnet, USA). Absorbance at 
595 nm of the samples was measured in a microplate spectrophotometer (Spark® 10M, Tecan, 
Switzerland). Bovine serum albumin (Sigma, USA) was used as an external standard for the 
calibration curve (0 – 1.2 mg/mL). The results were expressed as means of triplicates (mg 
protein/mL) ± standard deviation. 
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3. Results and Discussion 
 
The search of dietary natural compounds that can diminish post-prandial hyperglycemia peaks is 
of great interest. In this area, wines are very promising beverages due to their rich composition in 
polyphenolic compounds. Red wine has been extensively studied, existing some reports on its 
anti-diabetic potential. However, in white wine these health-promoting effects were not explored 
much.  
The main aim of this thesis was to evaluate the potential anti-hyperglycemic effect of white wines 
using an in vitro approach. For this purpose, the capacity of wines in inhibiting carbohydrates 
digestion enzymes (Part 1) and intestinal glucose transporters (GLUT2 and SGLT1) (Part 2) was 
studied using in vitro assays and cellular models.  
 
3.1. Part 1: White Wine Characterization and Evaluation of Carbohydrate Digestion 
Inhibitory Potential 
 
In a previous work of the host lab focused on “White Wine and Health”, the phytochemical content 
and antioxidant capacity of 4 white wines was evaluated. The results listed in table 3.1 are from 
the project report [104]  and were the basis of the work of this master thesis. First, the antioxidant 
and phytochemical characterization of white wines was accomplished, and the results are 
summarized in tables 3.1 and 3.2.  
 
Table 3.1: Phytochemical and antioxidant characterization of the samples. The results are expressed as 
mean ± SD. Results from the report of the project “White Wine and Health”.   
 TPC1 
(mg GAE/L) 
ORAC2  
(µM TEAC) 
HORAC3 
 (µM CAE) 
CAA4 
 (µM QE) 
Aveleda Douro Doc (2011) 283 ± 33 8226 ± 843 3669 ± 311 447 
Quinta da Aveleda (2011) 250 ± 30 7017 ± 811 3556 ± 395 464 
Aveleda Alvarinho (2011) 290 ± 34 6408 ± 562 4746 ± 272 424 
Conventual (2011) 279 ± 33 6986 ± 504 4014 ± 270 356 
1-  Total phenolic content (TPC) determined using Folin-Ciocalteau method. The results are expressed as mg of gallic 
acid /L of wine. 2- Rescue capability of peroxide radicals. The results are expressed as µmol of trolox equivalents /L of 
wine. 3- Inhibition capability of hydroxide radicals. The results are expressed as µmol of caffeic acid equivalents /L of 
wine. 4- Cellular antioxidant capacity: rescue capability of reactive species at cellular level using Caco-2 cell model and 
AAPH as oxidant agent. The results are expressed as µmol of quercetin equivalents /L. The method has an associated 
error inferior of 15%. 
 
In terms of antioxidant capacity (Table 3.1), no major differences were observed between the four 
wines, but the samples from Douro region present higher levels of antioxidant capacity: Aveleda 
Douro Doc yielded the highest ORAC value and Aveleda Alvarinho the highest HORAC value; 
the highest value of cellular antioxidant capacity is from Quinta da Aveleda. The total phenolic 
content (TPC) was similar for all tested samples, but again a Douro wine presented the highest 
phenolic content: Aveleda Alvarinho. The total phenolic content of white wines was in agreement 
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with the literature, and about 10 time less than the reported phenolic content for red wine 
[105,106]. Despite there being no differences between the total phenolic content of the analyzed 
white wines, the antioxidant activity of the samples differs and this result could be related with the 
presence of a specific compound and not with the total sum of compounds.  
In order to analyze the phenolic composition of each tested sample, LC-MS/MS was performed 
for the detection and quantification of specific phenolic compounds by using calibration curves of 
relevant standards. The quantification results are summarized in table 3.2.  
 
Table 3.2: Identification and quantification of phenolic compounds in the four white wine samples using 
LC-MS/MS with electrospray ionization. The results are expressed as mean ± SD of duplicate.  
 Wine Sample 
Aveleda 
Douro Doc 
(2011) 
Quinta da 
Aveleda 
(2011) 
Aveleda 
Alvarinho 
(2011) 
Conventual 
(2011) 
Id
e
n
ti
fi
e
d
 C
o
m
p
o
u
n
d
s
 (
m
g
/L
) 
Caffeic Acid 1.3 ± 0.14 1.35 ± 0.07 2.05 ± 0.07 1.25 ± 0.07 
p-Coumaric Acid 0.55 ± 0.07 0.55 ± 0.07 1.15 ± 0.07 0.65 ± 0.07 
Ferulic Acid NI NI NI < LOQ 
Gallic Acid 3.4 ± 0.14 3.95 ± 0.5 5.25 ± 0.35 2.55 ± 0.21 
Rutin < LOQ < LOQ < LOQ < LOQ 
Procyanidin B1 < LOQ 1 ± 0.14 2.5 ± 0.14 < LOQ 
Catechin < LOQ 0.84 ±0.09 1.1 ± 0.14 NI 
Gallocatechin NI NI 0.6 ± 0.0 0.9 ± 0.0 
Coutaric Acid 8.55 ± 0.5 3.6 ± 0.14 6.7 ± 0.0 4.3 ±0.07 
Fertaric Acid 13.2 ± 0.07 16.2 ± 0.0 22.3 ± 1.5 24.5 ± 0.42 
Caftaric Acid NI NI NI NI 
NI, not identified; LOQ, limit of quantification  
From the results presented in table 3.2 is evident that the identified compounds were mostly 
phenolic acids, more precisely hydroxycinnamic acids. This is in agreement with the literature, 
since hydroxycinnamic acids are identified as the phenolic compounds existing at higher 
concentrations in white wine [84]. Caffeic and p-coumaric acids were identified in all samples as 
simple acids, as well as coutaric acid. Ferulic acid was not identified in Douro region wines but 
was identified below the quantification limit in Conventual. However, fertaric acid (the ester of 
ferulic and tartaric acids) was identified and quantified in all wines and the highest concentration 
was obtained for Aveleda Alvarinho. Among all samples Aveleda Alvarinho was the wine that 
presented more variety of phenolic compounds at higher concentrations, particularly p-coumaric 
acid, gallic acid, procyadinidin B1 and catechin. Conventual presented the highest concentration 
of fertaric acid and the lowest of gallic acid. Aveleda Douro Doc was the sample that presented 
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the lowest concentrations and less variety of the different phenolic acids identified, although it had 
the highest amount of coutaric acid. The observed differences in phenolic composition between 
the four white wines were probably derived from the different types of grapes present in each 
wine (section 2.1). 
The α-amylase inhibitory potential of white wines was evaluated. Inhibition of pancreatic α-
amylase results in a decrease of the starch hydrolysis, diminishing the amount of oligosaccharides 
in the small intestine lumen that are substrates of brush border α-glucosidases, therefore 
preventing the absorption of simple sugars. The results are summarized in Figure 3.1. In this 
work, acarbose was used as a positive control and the results showed that this drug inhibited α-
amylase in a dose-dependent manner, yielding an IC50 value of 35.56 ± 1.37 mg/L (≈ 55.08 µM) 
(Appendix A, figure 6.1), in agreement with the literature [93,107]. 
Figure 3.1: Dose-response curves of Quinta da Aveleda (2011), Conventual (2011), Aveleda Alvarinho 
(2011) and Aveleda Douro Doc (2011). Results are expressed as mean ± SD of three independent 
experiments performed in triplicate. 
 
 All four white wines were efficient inhibitors of α-amylase, in a dose-dependent manner (Figure 
3.1). The IC50 values were determined from their correspondent dose-response curve using non-
linear regression and are presented in Table 3.3. 
 
Table 3.3: IC50 values (mg GAE/L) of the four white wine samples obtained from the respective dose-
response curves presented in Figure 3.1. Results are shown as mean ± SD of three independent 
experiments performed in triplicate. 
 
 
 
 
 
 
Sample 
IC50  
(mg GAE/L) 
Aveleda Alvarinho 
(2011) 
199.5 ± 3.11 
Aveleda Douro Doc 
(2011) 
258.3 ± 1.94 
Quinta da Aveleda 
(2011) 
140 ± 1.73 
Conventual (2011) 188.6 ± 2.09 
Concentration (log (mg GAE/L)) 
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The results showed that, when compared with acarbose, the IC50 values of all wines were higher, 
indicating lower inhibition capacity than the drug. Even so, the samples demonstrated to have a 
high inhibitory potential, with Quinta da Aveleda showing the most potent α-amylase inhibition, 
and Aveleda Douro Doc the weakest. Studies with white wine pomace had demonstrated that 
white grape skin residues were found to inhibit α-amylase with an equal or higher efficacy than 
acarbose, with IC50 values ranging from 12.5 to 27.4 mg GAE/L, about 10 times more potent than 
the values determined for white wine [93]. 
The α-glucosidase inhibitory potential of the four white wines was evaluated in rat small intestine 
α-glucosidases. Studies have demonstrated the advantages of using α-glucosidases of 
mammalian origin since they are biologically more relevant compared to purified yeast α-
glucosidases, mimicking more accurately the in vivo processes [92].  However, one of the main 
groups of macromolecules existing in white wine are polysaccharides [108]. Since some of these 
types of sugars are substrates to α-glucosidases, in order to eliminate their interference on the 
enzyme activity, phenolic fractions were collected in methanol by SPE. After the phenolic 
extraction, the samples were concentrated and all wines were evaluated at the same 
concentration factors (CF). Different concentrations of the wines were tested, namely CF 2.5 and 
CF 5. However, in this case, it was not possible to determine the IC50 value due to color 
interference of the samples with the enzymatic inhibition method used. Even using a control only 
to account for the color interference it was not possible to determine the percentage inhibitions 
for concentrations superior to CF 5 (data not shown). Therefore, percentage inhibitions at CF 5 
and CF 2.5 were determined and presented in Figure 3.2. Acarbose was used as a positive control 
and its dose-response curve was determined (Appendix A, Figure 6.2), yielding an IC50 value of 
31.9 ± 9.65 mg/L (≈ 49.4 µM) which is similar  to other reports [52,109,110]. 
 
 
 
 
 
 
 
Figure 3.2: Inhibitory effect of the tested white wines in rat small intestinal α-glucosidase. Results are 
expressed as mean ± SD of three independent experiments performed in triplicate.  
Among all samples, Quinta da Aveleda, which at the highest concentration tested (CF 5) reached 
about 50% inhibition, and Aveleda Alvarinho were the most potent inhibitors. These results are 
very low in comparison with the IC50 values found for white grape skins, whose values varied from 
3.9 mg GAE/L to 93.1 mg GAE/L, much lower than the polyphenolic concentrations tested  [93]. 
In another study, black tea was found to be a very potent α-glucosidase inhibitor, with IC50 values 
25 times higher than those determined for white grape skins [110]. It is noteworthy that the highest 
inhibitory potential observed for Quinta da Aveleda was not related with a higher polyphenolic 
concentration, since the tested concentration was the lowest (1250 mg GAE/L) of all four wines 
at CF 5. 
 
  737.5   1475 707.5   1415   625     1250  697.5   1395 
Concentration (mg GAE/L) 
Aveleda 
Alvarinho  
(2011)  
Aveleda Douro 
Doc (2011)  
Quinta da 
Aveleda (2011) 
Conventual 
(2011) 
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Aiming at evaluating if white wine phenolics can act synergistically with acarbose in inhibiting α-
glucosidase, three different concentrations of acarbose (1000 mg/L: 75% inhibition; 62.5 mg/L: 
50% inhibition; 1.95 mg/L: 35% inhibition) and one of each wine (CF 2.5) were tested and the 
results summarized in Figure 3.3.  
 
Figure 3.3: Inhibitory effect of combining acarbose and white wines in rat small intestinal α-glucosidase. The 
four wines were tested at the following concentrations: Aveleda Alvarinho, 737.5 mg GAE/L; Aveleda Douro 
Doc, 707.5 mg GAE/L; Quinta da Aveleda, 625 mg GAE/L; Conventual, 697.5 mg GAE/L. The results are 
expressed as means ± SD of three independent experiments performed in duplicate. Significant differences 
from acarbose are expressed with asterisks (ns P > 0.05; **P < 0.01 and ****P < 0.0001) by one-way ANOVA.  
 
Aveleda Alvarinho (2011) and Quinta da Aveleda (2011) in combination with acarbose showed 
significant (P < 0.01 and P < 0.0001) higher α-glucosidase inhibition than the drug alone. For the 
other wines, no improvements on the α-glucosidase inhibitory effect were observed when 
combined with the drug. The differences in response between wines could be related with their 
phenolic composition. Aveleda Alvarinho and Quinta da Aveleda could contain phenolic 
compounds that present synergy with acarbose. 
In order to identify the bioactive compounds responsible for the α-glucosidase inhibition and for 
the effect observed in combination with acarbose, pure phenolic standards were tested. Aveleda 
Alvarinho (2011) and Quinta da Aveleda (2011) contained approximately the same phenolic 
compounds that were reported in the literature as potential α-glucosidase inhibitors or whose 
structures suggested that they were good candidates. Thus, p-coumaric acid, caffeic acid, 
catechin and gallic acid were tested for their inhibitory potential. All compounds were tested in the 
same concentrations found in Aveleda Alvarinho. The results are presented in Figure 3.4 and the 
concentrations of the pure compounds tested summarized in Table 3.4. Aveleda Alvarinho 
inhibition percentage was used to assess the dependence with the pure compounds inhibition.  
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Figure 3.4: Inhibitory effect of pure phenolic compounds in rat small intestinal α-glucosidase, at three 
different concentrations of Aveleda Alvarinho wine CF: 2.5, 5 and 10. The concentrations of each tested 
compound are described in Table 3.4. Aveleda Alvarinho (2011) was tested at 737.5 mg GAE/L (CF 2.5) 
and 1475 mg GAE/L (CF 5). The results are expressed as means ± SD of three independent experiments 
performed in triplicate. Significant differences from gallic acid are expressed with asterisks (ns P > 0.05; *P 
< 0.05; **P < 0.01; ***P < 0.001 and ****P < 0.0001) by one-way ANOVA. Due to the increasing of color with 
concentration, it was not possible to determine a result for the wine at CF 10.   
 
Table 3.4: Tested concentrations of the pure compounds at the different concentration factors of Aveleda 
Alvarinho (2011) wine. 
 
Concentration (mg/L) 
CF 2.5 CF 5 CF 10 
p-Coumaric Acid 3 6 12 
Caffeic Acid 5.3 10.5 21 
Catechin 2.8 5.5 11 
Gallic Acid 13.3 26.5 53 
 
The results showed that gallic acid was the only pure phenolic compound that significantly 
inhibited α-glucosidase in a dose-dependent manner (P < 0.0001), reaching 60% enzymatic 
inhibition in the higher concentration tested. The other compounds, namely p-coumaric acid, 
caffeic acid and catechin, exerted approximately 35% inhibition at all three concentration factors 
tested. In order to understand if any of the tested compounds was responsible for the wine 
inhibition percentage previously observed, obtained inhibitions from the pure compounds were 
compared with Aveleda Alvarinho at concentration factors 2.5 and 5. Observing Figure 3.4 it 
appears that the effect exerted by gallic acid is very similar to the inhibition that Aveleda Alvarinho 
exerts in the enzyme at CF 2.5 and 5, suggesting that it could be the bioactive compound 
responsible of most of the inhibitory potential that the wine demonstrated. A statistical analysis 
was done in order to determine if gallic acid produced a significant different inhibition from p-
coumaric acid, caffeic acid and catechin, and if it were similar to the one produced by the wine. 
The results showed that in fact gallic acid did not produced a significantly different inhibition than 
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the wine, at each of the concentrations tested, and it was significantly different from the other pure 
compounds tested. Comparison between the remaining phenolic compounds revealed no 
statistically significant differences existed between them (data not shown). Thus, since gallic acid 
revealed to be a promising bioactive compound in α-glucosidase inhibition, a dose-response 
curve was performed and its IC50 was calculated (Figure 3.5).  
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Figure 3.5: Dose-response curve of gallic acid in inhibiting α-glucosidase. Results are expressed as mean 
± SD of three independent experiments performed in triplicate. 
Figure 3.5 showed that gallic acid produced a dose-dependent inhibition of the enzyme, yielding 
an IC50 of 32.28 ± 9.65 mg/L (≈ 195.6 µM).These results support the observations made by other 
researchers that studied gallic acid inhibitory activity in different models: yeast α-glucosidase, 
brush border membranes from rat and maltase at the apical side of Caco-2 cell model [111,112].  
Gallic acid was then combined with acarbose in order to evaluate if this phenolic compound 
present in white wine could act synergistically with the drug, improving the inhibition of this 
carbohydrate-degrading enzyme. For this, the combination of both compounds at the same 
concentration (1:1 ratio) was tested and the dose-response curve determined. The obtained 
results are in Figure 3.6.  
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Figure 3.6: Dose-response curves of gallic acid, acarbose and of gallic acid/acarbose combination in 1:1 
ratio. Results are expressed as mean ± SD of three independent experiments performed in triplicate.  
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The results in Figure 3.6 and the IC50 above demonstrated that gallic acid is a much weaker α-
glucosidase inhibitor than acarbose. When tested in the same proportion, gallic acid and 
acarbose, produced a much stronger inhibition than the observed in the isolated compounds, 
reaching approximately 100% inhibition in the highest concentration tested (100 mg/L). In order 
to determine if the observed combined effect of gallic acid and acarbose was synergy, additive 
effect or antagonism, the combination indexes (CI) for each tested concentration were calculated 
through Chou-Talalay method, using CompuSyn® software. The combination index equation 
allows the quantitative determination of the interaction, that can be synergism (CI < 1), additive 
effect (CI = 1) or antagonism (CI >1) [99]. The results from the software analysis of the tested 
combinations are in Appendix B. Overall, the resulting effect of the combination of gallic 
acid/acarbose was synergy (CI < 1) as expected. In fact, the presence of a very strong synergy 
between the two compounds was observed (CI < 0.1) [113]. 
Taken together, all these results indicated that although white wines presented lower phenolic 
content than red wines, they contain a wide variety of phenolic acids and are able to inhibit 
carbohydrate-digestion enzymes in vitro. Among all samples tested, Aveleda Alvarinho (2011) 
demonstrated to be the most promising white wine tested. This wine presented the highest 
concentration of total phenolic compounds and the most variety of different phenolic acids in its 
composition, as well as displayed a strong α-glucosidase inhibition and synergy with the drug 
acarbose. Importantly, this wine contained the highest gallic acid concentration, a phenolic 
compound with α-glucosidase inhibitory capacity and synergistic effect in combination with the 
drug. 
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3.2. Part 2: White wine in vitro Digestion and Evaluation of Glucose Absorption Inhibitory 
Potential 
 
Aveleda Alvarinho was the selected wine for the evaluation of glucose inhibitory potential due to 
the results previously obtained, which demonstrated the higher phenolic content of the wine, as 
well as its capacity to inhibit α-glucosidase, demonstrating synergy with acarbose. For this study, 
a new sample of Aveleda Alvarinho from a more recent harvest (2014) was analyzed.  Aveleda 
Alvarinho (2014) was characterized in terms of phenolic profile. Quantification of total phenolic 
content was assessed by the Folin-Ciocaulteu method and a concentration of 305.6 ± 25.6 mg 
GAE/L was determined, which is in agreement with the total phenolic content of Aveleda Alvarinho 
(2011) described in section 3.1 and with the total phenolic content reported in the literature for 
different white wines [105,114]. The phenolic profile of the wine was analyzed by HPLC-DAD at 
280 nm, 320 nm and 360 nm, which are the characteristic wavelengths of phenolic compounds, 
hydroxycinnamic acids and flavonoids, respectively, aiming at the identification and quantification 
of phenolic compounds of interest. Figure 3.7 presents the Aveleda Alvarinho (2014) phenolic 
profile. 
 
Figure 3.7: Phenolic profile of Aveleda Alvarinho (2014) recorded at 280 nm. Legend: 1– gallic acid, 2– 
neochlorogenic acid, 3– epicatechin, 4– caffeic acid, 5– p-coumaric acid. 
As presented in Figure 3.7, gallic acid, neochlorogenic acid, epicatechin, caffeic acid and p-
coumaric acid, were identified. Through the analysis of the chromatograms the presence of 
chlorogenic acid (isomer of neochlorogenic acid) and trans-piceid were observed in the sample. 
Both compounds were reported in the literature as existing in the white wine phenolic composition 
[115,116]. In contrast with other phytochemical studies of white wines, ferulic acid and resveratrol 
were not identified in the sample [117,118]. In fact, these relevant bioactive compounds 
associated to a decrease in intestinal glucose absorption through SGLT1 transporter, were also 
not present in Aveleda Alvarinho from 2011 nor in the other white wines analyzed by mass 
spectrometry (section 3.1) [68,77]. 
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Quantification of the identified compounds was achieved using calibration curves of pure 
standards and the results are presented in Table 3.5. 
Table 3.5: Concentration of the identified phenolic compounds in Aveleda Alvarinho (2014) by HPLC-DAD.  
Compound Concentration (mg/L) 
Gallic Acid 3.49 
Neochlorogenic Acid 21.49 
Epicatechin 32.67 
Caffeic Acid 2.66 
p-Coumaric Acid 0.54 
 
Results showed that the wine is very rich in neochlorogenic acid and epicatechin. Although it was 
reported in the literature that these compounds were present in the phenolic composition of white 
wines, the concentrations found were usually lower, 2.9 mg/L for neochlorogenic acid and 0.9 
mg/L for epicatechin [119]. However, one study with French white wine reported a concentration 
of epicatechin of 33.8 mg/L, similar to the result in Table 3.5 [118]. In future, further analysis 
should be done by HPLC-MS analysis, in order to confirm the present results and also quantify 
other phenolic compounds of interest that were detected in the HPLC-DAD-UV chromatograms. 
The concentrations of gallic acid and p-coumaric acid were lower in comparison with the results 
of Aveleda Alvarinho (2011) presented in section 3.1, although in agreement with the literature 
[105,120]. 
Since gastrointestinal digestion can change the phenolic composition of foods, altering phenolic 
bioaccessibility, Aveleda Alvarinho (2014) was subjected to a standardized static in vitro 
simulated digestion. In fact, gastrointestinal digestion involves changes in pH and the activity of 
proteolytic enzymes that could affect the phenolic composition of white wine. The digestion 
process was performed in four independent experiments and samples of the gastric and intestinal 
steps were collected and analyzed by HPLC-DAD. The comparison of the phenolic profiles of the 
four replicates is presented in Figure 3.8. 
 
 
 
 
 
 
 
 
 
Figure 3.8: Phenolic profiles of the four in vitro digestion replicates (1, 2, 3, 4) and digestion control 
(performed with Milli-Q water instead of wine) of Aveleda Alvarinho (2014), collected in the gastric phase (A) 
and the small intestinal phase (B). The results were obtained by HPLC-DAD and recorded at 280 nm. 
A)  B)  
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All replicates were characterized in terms of total phenolic content by the Folin-Ciocalteau 
method, in each digestion step, and the results are summarized in Figure 3.9.  
 
Figure 3.9: Total phenolic content of gastric and small intestinal white wine after simulated digestion. The 
results are expressed as mg of gallic acid equivalents/L and shown as mean of four independent 
experiments ± SD. 
Results from Figures 3.8 and 3.9 showed that the four different wine digestion samples presented 
high reproducibility. It is important to mention that during the digestion process the phenolic 
content of the wine suffered changes. Results from Figure 3.9 showed that after the gastric step 
the phenolic content lowered, although a marked increase is observed after the intestinal step 
relatively to the initial wine. The phenolic profiles and the phenolic content of Aveleda Alvarinho 
(2014) and the gastric and intestinal fractions are compared in Figure 3.10. Analysis of the 
chromatographic profile of the intestinal fraction in Figure 3.10 revealed the appearance of new 
peaks, some with considerable areas, such as the peak at 63 minutes. This increase in the 
phenolic content was probably due to the contribution of these newly formed compounds. In solid 
matrices such as grape berries, an increase in phenolic content has been reported after in vitro 
digestion due to the extraction of phenolic compounds from the skin of the fruit in the gastric 
phase, which increases the amount of bioaccessible polyphenols during the digestion, although 
the same was not reported for beverages and juices [121,122]. However, it should be noted that 
this increase could be from interference from the newly formed compounds that could have higher 
redox potential than their precursors, thus interfering with the Folin-Ciocalteu method [123]. 
Further analysis is necessary in order to understand which metabolites are formed following the 
in vitro digestion process.  
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Figure 3.10: Phenolic profiles of Aveleda Alvarinho (2014), gastric fraction and small intestinal fraction 
recorded at 280 nm, obtained by HPLC-DAD. 
The results presented in Figure 3.10 evidence changes between the two steps of the 
gastrointestinal process. Phenolic profiles of Aveleda Alvarinho (2014) and its gastric digested 
fractions were quite similar, although the intensity of most peaks was higher in the gastric sample. 
In the small intestinal fraction, there were significant alterations to the phenolic profile, since the 
intensity of some peaks decreased and new peaks appeared. Some peaks that appeared 
exclusively in the intestinal fraction were derived from solutions and enzymes used in the 
digestion process, as these peaks also appeared in the control of the experience (Figure 3.8). 
Next, the identification and quantification of the main bioactive phenolic compounds of both gastric 
and intestinal fractions was carried out by HPLC-DAD and the results are presented in Figure 
3.11 and Table 3.6. 
A) 
 
B) 
 
Figure 3.11: Phenolic profile of gastric (A) and small intestinal (B) fractions, recorded at 280 nm. Legend: 
1– gallic acid, 2– neochlorogenic acid, 3– epicatechin, 4– caffeic acid, 5– p-coumaric acid. 
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The identified phenolic compounds were quantified through use of calibration curves of pure 
standards. The results are summarized in Table 3.6. 
Table 3.6: Concentration of the identified phenolic compounds in the gastric and small intestinal digested 
fractions of Aveleda Alvarinho (2014) in replicate 3, by HPLC-DAD. 
Compound 
Concentration (mg/L) 
Aveleda 
Alvarinho 
(2014) 
Gastric in vitro 
digestion 
Small Intestinal 
in vitro digestion 
Gallic Acid 3.49 8.99 ND 
Neochlorogenic 
Acid 
21.49 22.98 4.66 
Epicatechin 32.67 46.15 17.55 
Caffeic Acid 2.66 3.35 < LOQ 
p-Coumaric Acid 0.54 2.45 < LOQ 
   ND, not detected; LOQ, limit of quantification 
In the gastric fraction of digested white wine, gallic acid, neochlorogenic acid, epicatechin, caffeic 
acid and p-coumaric acid were identified and quantified. Chlorogenic acid and trans-piceid were 
both identified in the sample, whereas ferulic acid and resveratrol were not present. 
Neochlorogenic acid was the only phenolic compound that did not show significant differences 
regarding its initial concentration in the wine. The concentration of the remaining compounds 
increased after the treatment. Among all compounds, epicatechin and gallic acid showed the 
highest increase, followed by p-coumaric acid, whereas caffeic acid only suffered a slight increase 
in concentration. The stability of phenolic compounds under gastric acidic conditions has been 
studied. The increase in concentration of gallic acid, caffeic acid and p-coumaric acid after gastric 
digestion has been reported in the literature and is mostly due to the acidic gastric conditions 
[121,124]. Phenolic compounds from natural sources exist mainly as glycosides and esters, being 
hydrolyzed to free acids under acid conditions [125,126]. It is known that hydroxycinnamic acids 
in wine and grapes are found mostly in the form of esters (caftaric, coutaric and fertaric acids), 
and the increased concentration of caffeic and p-coumaric acids are probably due to their release 
from the esters [83,126]. Gallic acid also mostly exists in wine in complex polymeric structures, 
that under the gastric conditions could be broken, liberating gallic acid monomers, which 
contribute to the increase of gallic acid concentration after this digestion step [124,127]. Other 
authors have shown that epicatechin was stable under these conditions and that chlorogenic acid 
was not only stable but also preserved its initial concentration [128–130].  
In this study, after the small intestine in vitro digestion step, neochlorogenic acid, epicatechin, 
caffeic acid and p-coumaric acid demonstrated marked concentration decreases. Trans-piceid 
was also found in the sample however the peak decreased in intensity. Caffeic and p-coumaric 
acids were identified, although their concentrations were below the limit of quantification. Similar 
decreases in phenolic acids concentration after in vitro digestion have been reported in the 
literature, because phenolic acids become unstable due to the mild alkaline conditions in the small 
intestine [121,128–130]. Gallic acid could not be identified in the sample due to the presence of 
other non-phenolic compounds derived from the gastric fluid that interfere with the analysis 
(retention time: 14.8 min). The peaks appeared in the beginning of the chromatogram with very 
high intensity, at the same time the gallic acid peak should appear. Results from the literature 
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reported a decrease in gallic acid concentration after intestinal digestion, which was expected due 
to its acidic nature [121,124]. Thus, further analysis should be done in order to determine the 
impact of intestinal digestion in gallic acid concentration. 
The present results, as well as previous results from the literature, revealed that the phenolic 
compounds from white wine were stable under gastric digestion, promoting the release of some 
free acids. However, the compounds are highly sensitive to mild alkaline conditions, suggesting 
that a portion of these compounds must undergo structural transformations, giving rise to different 
compounds with different proprieties. Further testing and other analytical methods should be 
employed in order to assess the extension of the transformations, as well the identification and 
characterization of the new compounds. In the future, it would be of great interest to simulate the 
last step of intestinal digestion with gut microbiota, in order to evaluate the transformations that 
polyphenols suffer before absorption in the colon. 
The effect of white wine and gastrointestinal digested white wine on intestinal glucose transport 
was then evaluated, using polarized Caco-2 cells. Caco-2 cell model has been used in this area 
to evaluate the effects of drugs and other compounds, such as phenolic compounds, in intestinal 
sugar absorption because of its high expression levels of both SGLT1 and GLUT2 transporters 
[131]. 
First of all, cytotoxicity of both wine and digested wine was assessed on Caco-2 cell monolayers. 
Samples and Caco-2 cells were incubated for one hour and the results are presented in Figure 
3.12. 
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Figure 3.12: Cytotoxic evaluation of Aveleda Alvarinho (2014) and its digested fraction on Caco-2 cells. 
Incubation = 1 h; Results are expressed as mean ± SD of two independent experiments performed in 
duplicate. 
The IC50 values for Aveleda Alvarinho (2014) and its digested fraction were determined. The 
results demonstrated that the wine was more toxic (IC50 456.4 ± 141.5 mg GAE/L) than its 
digested fraction (IC50 719.5 ± 5 mg GAE/L). The cytotoxic effect of Aveleda Alvarinho (2014) and 
digested fraction were also evaluated during a longer incubation time of 4 hours, however similar 
results were obtained (Appendix C). 
The potential of white wine and the gastric fraction in inhibiting glucose transport across the small 
intestinal epithelium was then evaluated. Firstly, with the objective of evaluating glucose transport 
across the cell monolayer (from the apical to the basolateral side) as well as cellular uptake, 
promoted by glucose transporters, controls under sodium-dependent and sodium-free conditions 
were compared relatively to initial glucose mass as percentage (Figure 3.13). 
35 
 
 
Figure 3.13: Distribution of glucose between apical side, basolateral side and cells after 30 minutes of 
incubation, as a percentage of initial glucose in apical side (t = 0 minutes). A single representative experiment 
is shown; however, results were similar for five independent experiments. 
Under sodium-dependent conditions SGLT1 and GLUT2 were both activated, which reflected in 
more amount of glucose that was transported from the apical to the basolateral side. On the other 
hand, under sodium-free conditions only GLUT2 was operating and glucose was transported at a 
lower rate, although an increase of glucose uptake was observed (Figure 3.13). Similar results 
already reported demonstrated that, under sodium-free conditions, the glucose transport rate 
decreased due to inactivation of SGLT1 and therefore the glucose uptake observed is solely done 
by GLUT2 [132]. 
The study of wine and the inhibitory potential of its digested fraction was then carried out under 
sodium-dependent and sodium-free conditions. Different concentrations of wine and digested 
wine were tested according to polyphenol content, and dose-response curves were determined 
under both conditions (Figure 3.14). Known inhibitory compounds of SGLT1 and GLUT2 were 
used as positive controls of the experiments. Phloridzin (0.5 mM) was used under sodium-
dependent conditions, inhibiting SGLT1 by 39.9 ± 3.9%. Phloretin (0.5 mM) inhibited GLUT2 
under sodium-free conditions by 89.1 ± 1.8%.  
Figure 3.14: Effect of Aveleda Alvarinho (2014) and its gastrointestinal digested fraction on glucose transport 
across Caco-2 cells monolayers seeded in Transwell® inserts. Concentration of transported glucose was 
measured under sodium-dependent (A) and sodium-free (B) conditions. Results are expressed as mean ± 
SD of two independent experiments. 
The inhibition of intestinal glucose absorption could result in a decrease in glucose concentration 
in plasma [73]. Both samples inhibited transported glucose in a dose-dependent manner under 
both conditions, allowing the determination of IC50 values, presented in Table 3.7. 
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Table 3.7: IC50 values (mg GAE/L) of Aveleda Alvarinho (2014) and gastrointestinal fraction, obtained from 
the respective dose-response curves, under sodium-dependent and sodium-free conditions. Results are 
expressed as mean ± SD of two independent experiments. 
 
 
 
 
 
 
Overall, the digested fraction of Aveleda Alvarinho (2014) displayed stronger glucose transport 
inhibition than the wine, under both conditions, although the differences were not significant. The 
results presented in Table 3.7 show that the concentration required to decrease glucose transport 
by 50% was lower for the sample subjected to the gastrointestinal digestion but both samples 
were equally more active in sodium-dependent conditions (lower IC50). The inhibitory potential of 
apple and strawberry extracts has been reported in the literature. Under sodium-dependent and 
sodium-free conditions, both Aveleda Alvarinho (2014) and its digested fraction were more potent 
inhibitors of glucose transport than the strawberry extract. On the other hand, apple extract and 
wine yielded similar IC50 values under sodium-dependent conditions. However, when sodium was 
absent from the medium, apple extract demonstrated to be a more potent inhibitor of GLUT2 than 
Aveleda Alvarinho (2014) [73]. 
The effect of white wine and gastrointestinal digested white wine on glucose uptake by Caco-2 
cells was also evaluated, under sodium-dependent and sodium-free conditions. In Figure 3.15 
the glucose cellular uptake under sodium-dependent (Figure 3.15A) and sodium-free (Figure 
3.15B) conditions of Aveleda Alvarinho (2014) and its gastrointestinal digested fraction is 
presented. 
Figure 3.15: Effect of Aveleda Alvarinho (2014) and its gastrointestinal digested fraction on glucose uptake 
by Caco-2 cells. Intracellular concentration of glucose was measured under sodium-dependent (A) and 
sodium-free (B) conditions. Results are expressed as mean ± SD of two independent experiments. 
The results presented in Figure 3.15 suggest that both samples were more effective under 
sodium-free conditions. In the case of sodium-dependent conditions, polyphenols of Aveleda 
Alvarinho (2014) revealed to be more efficient inhibitors of glucose uptake than its digested 
fraction. Because the determined uptake percentages barely exceeded 50% inhibition, lower 
concentrations should be tested in order to determine IC50 values. Overall, both samples were 
effective inhibitors of glucose uptake under sodium-dependent and sodium-free conditions. 
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Although the concentrations of phenolic compounds present in the wine decreased after gastric 
digestion, an increase in phenolic content was observed after intestinal digestion and this 
intestinal digested fraction reduced glucose transport more efficiently. Phenolic compounds are 
subject to metabolism in the small intestine, which results in structural changes that could result 
in altered biological activity [133,134]. In fact, it has been reported that metabolites from dietary 
phenolic compounds can be more active than their precursors in inhibiting glucose transport 
across Caco-2 cell monolayers [132]. Since the required amount of both samples to decrease 
glucose transport is lower in sodium-dependent conditions and no significant differences were 
found in uptake between both conditions, this suggests that SGLT1 could be the component of 
glucose transport in the small intestine more sensitive to the action of white wine phenolic 
compounds. Phenolic compounds from other plant-derived beverages have shown similar 
glucose transport inhibition mechanism. In particular, green tea galloylated polyphenols have 
been reported as inhibitors of glucose transport through SGLT1 competitive inhibition, in brush 
border membrane vesicles from rabbit small intestine [135].    
Aiming at identifying bioactive compounds derived from white wine that could exhibit inhibitory 
effect in glucose transport, standard phenolic compounds, namely p-coumaric acid, gallic acid, 
resveratrol and epicatechin, were selected. Gallic and p-coumaric acids were abundant phenolic 
acids present in Aveleda Alvarinho. Epicatechin was also present at high concentration in the 
wine and was reported in the literature as a potential glucose transport inhibitor [135]. Although 
resveratrol was not present in this white wine, it is a very promising compound having been 
already reported as a potential inhibitor of SGLT1 glucose transporter [77]. These compounds 
were tested at 2.5 mM concentration and preliminary results of their effect on glucose transport, 
under both sodium-dependent and sodium-free conditions, are presented in Figures 3.16. 
 
Figure 3.16: Effect on glucose transport across Caco-2 cells monolayers of p-coumaric acid, gallic acid, 
resveratrol and epicatechin at 2.5 mM concentration. Concentration of transported glucose was measured 
under sodium-dependent (black) and sodium-free (grey) conditions. Results are expressed as mean ± SD 
of duplicate. Significant differences from the control are expressed with asterisks (ns P > 0.05 and ***P < 
0.001) by one-way ANOVA.   
Results from Figure 3.16 (2.5 mM concentration) showed that the pure phenolic acids did not 
significantly affect glucose transport. In contrast, resveratrol exerted a significant (P < 0.001) 
decrease in basolateral glucose concentration, inhibiting glucose transport by approximately 80%. 
Epicatechin led to a more modest inhibition of approximately 20%, however this effect was not 
significant (P > 0.05). No major differences were observed between sodium-dependent and 
sodium-free conditions. 
The most promising compounds were analyzed at a lower concentration (0.5 mM), represented 
in Figure 3.17.  
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Figure 3.17: Effect on glucose transport across Caco-2 cells monolayers of p-coumaric acid, resveratrol, 
phloridzin and phloretin at 0.5 mM concentration. Concentration of transported glucose was measured under 
sodium-dependent (black) and sodium-free (grey) conditions. Results are expressed as mean ± SD of 
duplicate. 
 
The results presented in Figure 3.17 showed that resveratrol and p-coumaric acid in both 
conditions did not show a different effect from that observed at 2.5 mM (Figure 3.16), suggesting 
that the inhibition was not dose-dependent. Resveratrol revealed to be a more potent inhibitor of 
glucose transport than phloridzin, under sodium-dependent conditions. However, under sodium-
free conditions, phloretin displayed the most effective inhibition. More studies should be 
performed in order to confirm these results, as well as to assess the dependence of epicatechin 
effect with concentration. 
Overall, the obtained results for pure compounds were in line with the existing studies in the 
literature. Most phenolic acids were reported as weak inhibitors of glucose uptake, in vitro. Gallic 
and caffeic acids reduced glucose uptake by rat brush border membrane vesicles, under sodium-
dependent conditions, by 10% and 35% [60]. In Caco-2 cells, both compounds, as well as other 
phenolic acids, did not show significant effects on glucose uptake [61]. However, in vivo studies 
with diabetic rats demonstrated that intravenous administration of caffeic acid and oral 
administration of an extract containing high concentration of chlorogenic acid decreased plasma 
glucose concentration, suggesting that phenolic acids could have an effect as anti-hyperglycemic 
agents [136,137]. The effect of flavonoids on intestinal glucose transport by GLUT2 expressed in 
Xenopus laevis oocytes has been described [65]. In contrast with the results presented in Figures 
3.16 and 3.17, epichatechin was reported as having a significant inhibitory effect on glucose 
uptake by Caco-2 cells under sodium-dependent conditions [61]. Since epicatechin was 
quantified in Aveleda Alvarinho (2014) in a relatively high concentration, further studies should be 
done to evaluate the anti-hyperglycemic potential of this phenolic compound. The potential 
benefits of resveratrol in several diseases are well documented in the literature, although its 
potential to modulate glucose absorption was not much studied. However, it was demonstrated 
that this phenolic compound could decrease glucose transport and uptake in the intestine by 
inhibiting SGLT1 in porcine jejunum and ileum [77]. Although resveratrol was not identified in the 
tested white wine it is an important constituent of grapes and by-products, being found in red wine 
and some white wines [105]. Thus, resveratrol extracted from winemaking by-products could be 
incorporated in white wine without dramatically change its chemical and sensorial proprieties. 
Therefore, there is interest to explore and study the anti-hyperglycemic potential of resveratrol, 
as well as the extent of how gastrointestinal digestion affects its stability and what transformations 
could occur before the compound reaches the target. 
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Literature reports on phenol-rich all-extracts and beverages demonstrate that the mixtures usually 
produced more significant effects on glucose transport and uptake than the pure identified 
phenolic compounds [132,138]. The results presented above evidence the same: white wine and 
digested wine produced a more potent effect than the pure compounds identified in the samples. 
These observations could be explained by the fact that, in a mixture, phenols can interact with 
one another, acting additively or synergistically, leading to enhancement of their activity [139,140]. 
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4. Conclusions  
 
Although the beneficial effect of moderate red wine consumption in Health is well known and 
widely supported by scientific evidence, there are few reports evaluating the bioactivity of white 
wines probably due to their lower content in phenolic compounds. In this thesis, white wines 
derived from Douro and Alentejo, produced with different grape varieties, were investigated for 
their content in phenolic compounds and their capacity in inhibiting carbohydrate-digestion 
enzymes and intestinal glucose transporters, aiming at identifying promising inhibitory 
compounds with positive impact in type 2 diabetes. 
Among the four white wines analyzed, Aveleda Alvarinho distinguished itself for presenting a 
higher phenolic content, particularly in phenolic acids such as gallic, caffeic and p-coumaric acid. 
Despite the fact that the inhibitory effect of this wine against α-glucosidase activity was not 
relevant when compared with other plant-derived products (e.g. teas, wine pomace and berry 
extracts), the phenolic fraction of this wine enhances the inhibitory potential of acarbose, a 
commonly used anti-diabetic drug that impairs glucose absorption in the small intestine through 
inhibition of these carbohydrate-digestion enzymes. This effect was suggested to be related with 
the phytochemical content of this wine, gallic acid being pointed as the main contributor for this 
effect. Importantly, Aveleda Alvarinho demonstrated inhibitory capacity of glucose transport, 
acting on SGLT1 and GLUT2 intestinal glucose transporters in Caco-2 cell line and the in vitro 
gastrointestinal digestion process did not compromise the bioactivity of the wine. Amongst the 
pure phenolic compounds tested, resveratrol emerged as a potential inhibitor of both glucose 
transporters, although the inhibitory potential of other phenolic compounds should also be 
explored.  
Overall, white wine constitutes a promising source of bioactive compounds with positive impact 
in T2DM. Although the concentration of bioactive compounds in white wine is not very high, 
strategies can be adopted to enhance the health promoting effect, such as fortifying the wine with 
bioactive compounds. Future studies should be performed to identify more bioactive compounds 
from white wine, such as ε-viniferin and trans-piceid, as well a full characterization of the gastric 
and intestinal fractions, in order to evaluate the structural biotransformations that phenolic 
compounds undergo until reaching their sites of action. Moreover, the study of phenolic 
compounds involved in the inhibition of glucose transport is required to understand the 
mechanism of action of white wine, allowing to explore these effects in terms of functional food. 
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6. Appendix  
 
Appendix A:  α – Amylase and α – Glucosidase Acarbose Dose-Response Curves 
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Figure 6.1: α-Amylase dose-response curve of acarbose. IC50 value of 35.56 ± 1.37 mg/L (≈ 55.08 µM). 
Results are expressed as mean ± SD of three independent experiments performed in triplicate. 
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Figure 6.2: α-Glucosidase dose-response curve of acarbose. IC50 value of 31.9 ± 9.65 mg/L (≈ 49.4 µM). 
Results are expressed as mean ± SD of three independent experiments performed in triplicate. 
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Appendix B: α – Glucosidase CompuSyn® Synergy Analysis  
 
Table 6.1: Combination study of the effect of acarbose and gallic acid (1:1 ratio). The analysis was done by 
calculation of the combination index (CI) using CompuSyn®. CI < 1, synergy; CI = 1 additive effect; CI > 1, 
antagonism [113]. 
Acarbose (mg/L) Gallic Acid (mg/L) Effect CI 
100.0 100.0 0.938 4.31E-6 
50.0 50.0 0.8162 0.00217 
25.0 25.0 0.6972 0.04423 
12.5 12.5 0.5843 0.35857 
6.25 6.25 0.5568 0.33789 
3.13 3.13 0.5204 0.38699 
1.56 1.56 0.5025 0.28902 
0.78 0.78 0.4471 0.50720 
0.39 0.39 0.4406 0.29425 
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Appendix C: Cytotoxicity of Aveleda Alvarinho (2014) and Digested Aveleda Alvarinho 
(2014) - 4 Hours of Incubation 
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Figure 6.3: Cytotoxic evaluation of Aveleda Alvarinho (2014) on Caco-2 cells. Incubation = 4 h; Results are 
expressed as mean ± SD of three independent experiments performed in triplicate. 
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Figure 6.4: Cytotoxic evaluation of intestinal digested Aveleda Alvarinho (2014) on Caco-2 cells. Incubation 
= 4 h; Results are expressed as mean ± SD of three independent experiments performed in triplicate. 
 
 
 
 
